Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 13,177-13,188 of 23,847
Drug study icon
TerminatedNCT03784222

Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients

This study exists to explore whether this type of care could improve care and understanding. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

Multiple locations, including Beijing
SchizophreniaDrugA study involving a medication or substance.From 18 Years to 45 Years
Countries
China
Sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Condition
Schizophrenia
Behavioral study icon
CompletedNCT05314153

Effects Zulresso on Postpartum Psychosis

This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

In Chapel Hill
SchizophreniaBehavioralFrom 18 Years to 45 Years
Countries
United States
Sponsor
University of North Carolina, Chapel Hill
Condition
Schizophrenia
Device study icon
CompletedNCT05006365

EffectsOfTranscranialPulseStimulationOnDepression-PilotRCT

This summary needs review. Please check the official study record and contact the research team for details.

In Hong Kong
DepressionDeviceA study involving a tool, app, wearable, test, or medical device.Over 18 Years
Countries
China
Sponsor
The Hong Kong Polytechnic University
Condition
Depression
Drug study icon
OngoingEUCTR 2010-018416-33

Effets du Fénofibrate durant la première année de schizophrénie (effects of Fenofibrate® in first year of schizophrenia)

This study is looking at whether FENOFIBRATE MYLAN 200 mg, gélule can help people with schizophrénia or Elderly. Participants receive the study medicine FENOFIBRATE MYLAN 200 mg, gélule and complete study visits and assessments.

In France
SchizophreniaOther
Countries
France
Sponsor
Centre Hospitalier Régional et Universitaire de Lille
Condition
Schizophrenia
Drug study icon
CompletedNCT01439126

Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder

This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

Location not clearly listed
ADHDDrugFrom 6 Years to 17 Years
Countries
Sponsor
Concordia Pharmaceuticals Inc., Barbados
Condition
ADHD
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.